BASF to expand capacity for ethylene oxide and several downstream derivatives at its Verbund site in Antwerp, Belgium

LUDWIGSHAFEN, 27-Jul-2018 — /EuropaWire/ — BASF pursues a significant capacity expansion of the integrated ethylene oxide complex at its Verbund site in Antwerp, Belgium. The project includes capacity expansions for ethylene oxide and for several downstream derivatives, such as surfactants.

In Europe, BASF operates ethylene oxide plants in Antwerp and Ludwigshafen with a combined capacity of 845,000 metric tons per year. The company is the largest producer of ethylene oxide derivatives in the region. Major ethylene oxide derivatives are surfactants, ethanol amines, glycol ethers, polyether polyols and other specialty products used in a wide range of industries such as home and personal care, industrial applications and the automotive industry.

BASF intends to further strengthen its backward integration into ethylene oxide to support continued growth of its customers in downstream markets. The final investment decision is expected to be made in 2019.

About BASF
At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. The more than 115,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into five segments: Chemicals, Performance Products, Functional Materials & Solutions, Agricultural Solutions and Oil & Gas. BASF generated sales of €64.5 billion in 2017. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (BAS). Further information at  www.basf.com.

SOURCE: BASF SE

MEDIA CONTACT
Claudia Neumair
+49 621 60-59958
Send Mail

EDITOR'S PICK:

EuropaWire PR Editors

Recent Posts

Standard Chartered Raises Over USD 1 Billion in Signature CIO Funds

(IN BRIEF) Standard Chartered Bank has successfully raised more than USD 1 billion through its…

1 hour ago

WACKER Expands Biopharmaceutical Capabilities in the USA for Advanced Therapies

(IN BRIEF) WACKER is strategically enhancing its BIOSOLUTIONS life-science division by bolstering capacities in biopharmaceuticals…

2 hours ago